Effectiveness of the seasonal flu vaccine and new production methods
Despite a mismatch between the 2014–2015 seasonal flu vaccine and circulating strains, the flu jab is still the best way to protect people in at-risk groups.
There are three types of influenza viruses – A, B and C – but only types A and B cause seasonal epidemics in humans. Type A viruses can also cause pandemics and are classified into subtypes according to the variety and combinations of two surface proteins, hemagglutinin (HA) and neuraminidase (NA). Circulating flu viruses continuously evolve, so seasonal vaccines contain a mix of two influenza A subtypes and one or two influenza B viruses, which are reviewed each year by the World Health Organization (WHO).
The WHO coordinates a network called the Global Influenza Surveillance and Response System (GISRS), consisting of 142 National Influenza Centres (NICs) as well as various collaborating centres and laboratories. Recommendations for vaccine composition are made by the WHO in February for the following winter’s flu season in the Northern hemisphere. Antigenic drift of circulating viruses can occur in the interim, leading to a mismatch between the vaccine and circulating strains, and low vaccine effectiveness.
Speeding up production
Traditional egg-based vaccine production is more than 70 years old, takes around six months and uses millions of chicken eggs. Alternative production processes have been developed that aim to speed up manufacturing time and scale-up, as well as improve vaccine efficacy. Importantly, these processes do not rely on eggs, which could be in scarce supply if a bird flu pandemic hits.
Working towards a universal vaccine
Many researchers are trying to create a vaccine that provides broad protection against existing and newly emergent strains, eliminating the need for annual vaccination. Some universal flu vaccines aim to stimulate a cellular immune response, as opposed to the antibody-based response targeted by current vaccines. A cellular response is the mechanism underlying naturally acquired immunity. Even a vaccine more broadly protective within a single subgroup would offer advantages, and could provide some intra-seasonal protection, most likely in combination with conventional vaccines.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069647
Recommended from Pharmaceutical Press
This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.£57.00Buy now
Pharmacy Registration Assessment Questions 2 features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own. All questions are in line with current GPhC guidance, enabling you to prepare for the pharmaceutical pre-registration exam with confidence.£35.00Buy now
Pharmacy Registration Assessment Questions 3 is the third volume in a series that follows on from the previous, highly popular Pharmacy Registration Assessment Questions 2. It features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own.£35.00Buy now
Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.£33.00Buy now